Claudia Ordonez, Chief Medical Officer at Keros Therapeutics, Inc. (KROS), sold 1,000 shares at $65.35 ($65K) on 2021-02-11, disclosed to the SEC on 2021-02-16.
Scheduled sale ($65k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $63.10 | 175 | $11K | 17.0% |
| 2 | $64.17 | 312 | $20K | 30.9% |
| 3 | $65.35 | 216 | $14K | 21.8% |
| 4 | $66.19 | 295 | $20K | 30.1% |
| 5 | $68.05 | 2 | $136 | 0.2% |
| Total | $64.84 avg | 1,000 |
| $65K |
| 100% |
| Filing → |
| KROS | SELL | 2021-04-14 | $60K | — | Filing → |
| KROS | SELL | 2021-03-15 | $65K | — | Filing → |